H. Wilke

12.0k total citations · 3 hit papers
142 papers, 8.3k citations indexed

About

H. Wilke is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, H. Wilke has authored 142 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pulmonary and Respiratory Medicine, 80 papers in Oncology and 48 papers in Surgery. Recurrent topics in H. Wilke's work include Gastric Cancer Management and Outcomes (78 papers), Colorectal Cancer Treatments and Studies (58 papers) and Esophageal Cancer Research and Treatment (26 papers). H. Wilke is often cited by papers focused on Gastric Cancer Management and Outcomes (78 papers), Colorectal Cancer Treatments and Studies (58 papers) and Esophageal Cancer Research and Treatment (26 papers). H. Wilke collaborates with scholars based in Germany, United States and United Kingdom. H. Wilke's co-authors include M. Stahl, Martin Stuschke, Hans‐Joachim Meyer, Martin K. Walz, S. Seeber, Eric Van Cutsem, Wilfried Budach, Nils Lehmann, A. Harstrick and David Cunningham and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

H. Wilke

136 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →
Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus

2005 935 citations M. Stahl, Martin Stuschke et al. Journal of Clinical Oncology profile →
Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction

2009 654 citations M. Stahl, Martin K. Walz et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by H. Wilke

Since Specialization

Citations

This map shows the geographic impact of H. Wilke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Wilke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Wilke more than expected).

Fields of papers citing papers by H. Wilke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Wilke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Wilke. The network helps show where H. Wilke may publish in the future.

Co-authorship network of co-authors of H. Wilke

This figure shows the co-authorship network connecting the top 25 collaborators of H. Wilke. A scholar is included among the top collaborators of H. Wilke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Wilke. H. Wilke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study 2016 ·Annals of Oncology ·Eric Van Cutsem, Kei Muro, David Cunningham, G. Bodoky, Alberto Sobrero, Stefano Cascinu, Jaffer A. Ajani, Atsushi Ohtsu, (unknown), S-E. Al-Batran, Zev A. Wainberg, Rebecca R. Hozak, Haojun Ouyang, Symantha Melemed, D. Ferry, H. Wilke	5
2	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma 2016 ·Annals of Oncology ·Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, T.-Y. Kim, David Cunningham, P. Rougier, Kei Muro, Astra M. Liepa, Kumari Chandrawansa, Michael Emig, Atsushi Ohtsu, H. Wilke	55
3	Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status 2014 ·Annals of Oncology ·S. Al-Batran, Eric Van Cutsem, (unknown), G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae Yong Kim, David Cunningham, P. Rougier, Kei Muro, (unknown), (unknown), Michael Emig, Atsushi Ohtsu, H. Wilke	1
4	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial breakdown → 2014 ·The Lancet Oncology ·H. Wilke, Kei Muro, Eric Van Cutsem, (unknown), G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu	1715
5	Treatment Strategies in Gastric Cancer 2011 ·Deutsches Ärzteblatt international ·Hans‐Joachim Meyer, H. Wilke	74
6	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 2007 ·Annals of Oncology ·C.-H. Köhne, Jacques De Grève, J. T. Hartmann, István Láng, Philippe Vergauwe, Karl‐Friedrich Becker, D. Braumann, E. Joosens, Lothar Müller, Jos Janssens, Carsten Bokemeyer, Peter Reimer, Hartmut Link, E. Späth‐Schwalbe, H. Wilke, Harry Bleiberg, Jan Van den Brande, Muriel Debois, Ullrich Bethe, Eric Van Cutsem	127
7	Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO 2005 ·Annals of Oncology ·Christian Kollmannsberger, Wilfried Budach, M. Stahl, N. Schleucher, Thomas Hehr, H. Wilke, Jan Schleicher, U. Vanhoefer, E. C. Jehle, Karin Oechsle, Tanja Trarbach, (unknown), Lothar Kanz, J.T. Hartmann, Carsten Bokemeyer	31
8	Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy 2005 ·Oncology Research and Treatment ·M. Stahl, Christian Müller, (unknown), H. Wilke	16
9	Randomized phase III trial in locally advanced squamous cell carcinoma of the esophagus: Neoadjuvant radiochemotherapy followed by surgery vs. definitive radiochemotherapy 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Martin Stuschke, M. Stahl, H. Wilke, Martin K. Walz, S. Seeber, Bodo Klump, Wilfried Budach, H. D. Becker, D. Haeussinger, G Schmitt, (unknown)	1
10	New systemic frontline treatment for metastatic colorectal carcinoma 2004 ·Cancer ·Ada Braun, W. Achterrath, H. Wilke, U. Vanhoefer, A. Harstrick, P. Preusser	63
11	Application of Adjuvant Chemotherapy in Colorectal Cancer – a Survey in the Region of Essen, Germany 2004 ·Oncology Research and Treatment ·Michael Ståhl, (unknown), Christian Müller, (unknown), H. Wilke	0
12	Current treatments and future perspectives in colorectal and gastric cancer 2003 ·Annals of Oncology ·H. Wilke, Eric Van Cutsem	45
13	Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphon acetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma 1997 ·Annals of Oncology ·A. Harstrick, C.-H. Köhne, Wolfgang Hiddemann, P. Preusser, Dirk Strumberg, T. Berns, S. Seeber, H. Wilke, Hans‐Joachim Schmoll	2
14	Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma 1994 ·Annals of Oncology ·H.J. Weh, H. Wilke, Judith Dierlamm, U. Klaassen, (unknown), H. J. Illiger, Andreas Schalhorn, E.D. Kreuser, (unknown), B. Steinke, William P. Weber, Oswald Burkhard, (unknown), J. Pfitzner, (unknown), Richard M. Kriebel, D. K. Hossfeld	65
15	Esophageal Cancer: Current status and future directions in the treatment of localized esophageal cancer 1994 ·Annals of Oncology ·H. Wilke, J. R. Siewert, U. Fink, M. Stahl	13
16	Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus 1992 ·Cancer Chemotherapy and Pharmacology ·A. Harstrick, Carsten Bokemeyer, P. Preusser, (unknown), Hans‐Joachim Meyer, Michael Ståhl, H. Knipp, Hans‐Joachim Schmoll, H. Wilke	16
17	Antitumour effect and symptomatic control with interferon α2b in patients with endocrine active tumours 1992 ·European Journal of Cancer ·C. Schöber, Hans‐Joachim Schmoll, H. Poliwoda, Frank Schuppert, M. Stahl, Carsten Bokemeyer, H. Wilke, Jared Weiss	17
18	Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia 1990 ·Hämatologie und Bluttransfusion ·Hartmut Link, M. Freund, H. Diedrich, H. Wilke, (unknown), Michael Henke, H. Wandt, (unknown), G. Schlimok, Rüdiger Hoffmann, (unknown), H. Poliwoda	10
19	Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. 1989 ·Journal of Clinical Oncology ·H. Wilke, P. Preusser, U. Fink, U. Gunzer, H J Meyer, Jochen Meyer, J. R. Siewert, W. Achterrath, Luigi Lenaz, H. Knipp	228
20	Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2 b 1988 ·Annals of Hematology ·M. Freund, Peter von Wussow, (unknown), H. Mohr, Ulrich Pohl, (unknown), H. Link, H. Wilke, H. Poliwoda	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact